Back

SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Novel drugs for cardiovascular diseases Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Chao Lv

Shanghai (China)

5 More presentations in this session

Presentation thumbnail
Zibotentan in microvascular angina: a randomized, placebo-controlled, crossover trial
Doctor A. Morrow (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Inhibition of ceramide de novo synthesis mitigates atherosclerosis
Miss S. Chong (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Experimental evidence on colchicine's mode of action in human carotid artery plaques
Mrs I. Steenbuck (Freiburg, DE)
Abstract Slides Video
Presentation thumbnail
The short-term prognosis of salvianolate use during hospitalization in patients with acute myocardial infarction
Doctor R. Guo (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Safety, tolerability, and basic pharmacokinetic parameters of AUX-001, a once-daily extended release nicorandil in healthy volunteers under fasting and fed conditions
Doctor U. Tigoer (Saratoga Springs, US)
Abstract Slides Video

Access the full session

Session thumbnail
Novel drugs for cardiovascular diseases
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
What’s new in LDL lowering?
thumbnail
Congress Presentation
Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources